In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.
●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.

(millions yen)	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03
Total assets	247,592	265,126	272,679	272,791	285,600	293,571	278,496	294,535	315,459	322,858
Net assets	177,935	199,680	200,492	205,866	220,619	229,043	210,019	228,273	246,425	255,027
Liabilities	69,657	65,445	72,186	66,924	64,980	64,528	68,477	66,261	69,034	67,831
Equity ratio	67.2%	70.4%	69.3%	71.1%	72.9%	73.6%	75.2%	77.2%	77.8%	78.7%